For the first time, a study manages to quantify the effect of vaccines against Covid-19 in patients with heart failure: they are over 80% more likely to live longer than non-vaccinated patients.
Since vaccines against Covid-19 have become available, the people with heart problems have always been listed in the list of fragile subjects. Today, a study measured the benefits in people with heart failure: from the analysis on almost 150,000 patients suffering from this condition it emerged that the vaccinated people they have an 82% greater chance of living longer compared to unvaccinated people, reducing the mortality rate from all causes.
The study also revealed that during the six months of observation, they had undergone the Covid-19 vaccine it also reduced the risk of being hospitalized for heart failure, as well as determining a lower probability of contracting the infection. Since January 2024, new updated and effective vaccines have been available against the new variants of Sars-Cov-2, which arrived in Italy in recent weeks.
The results after six months of study
This study is the first – the authors explained – to show a clear benefit of vaccination on people suffering from heart failure, a problem that concerns beyond 64 million people all over the world.
Myocarditis and thrombosis: the real risks of the Covid vaccine in a study on 99 million vaccinated people
After observing the patients participating in the study for a period of six months, the researchers quantified how the vaccine had affected their health and their life expectancy. Let’s start from the most significant data: vaccinated patients showed 82% less likely to die for all causes compared to the unvaccinated. Even the risk of being hospitalized for heart failure appeared lower, almost halved (47% less), and that of contracting the coronavirus was 13% lower.
What emerged from the study on heart failure and vaccines
The study was presented during the World Heart Failure Congress, in Lisbon, on May 11, 2024 and was conducted by doctors froml National Health Insurance Service Ilsan Hospital of Goyang, South Korea, using patient data collected in the hospital database.
To carry out the study, the researchers started from an audience of 651,127 patients with an average age of 69.5 years, 50% women and 50% men. Of these, 538,434 (83%) were classified as vaccinated (had received two or more doses) and 112,693 (17%) as unvaccinated.
However, to exclude the impact of other factors on the participants’ overall health, the researchers only considered patients who could be matched based on gender, age and other health conditions. In this way the audience was selected and reduced to 73,559 patients vaccinated And 73,559 unvaccinated patients. The study therefore, explain the authors, provides new evidence in favor of the administration of anti-Covid vaccines in people with heart failure, however they reiterate that they do not represent a universally valid rule and that in patients with particular conditions we must always refer to the risk assessment by doctors.
